Apollomics Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer Posted on 2024-03-042024-03-16 by maxproadmin More >>
Apollomics Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia Posted on 2024-01-032024-03-13 by maxproadmin More >>
Apollomics Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation Posted on 2023-12-042024-03-13 by maxproadmin More >>
Apollomics Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC) Posted on 2023-11-282024-03-13 by maxproadmin More >>
Apollomics Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer Posted on 2023-11-162024-03-13 by maxproadmin More >>
Apollomics Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation Posted on 2023-10-312024-03-13 by maxproadmin More >>
Apollomics Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion Posted on 2023-10-262024-03-13 by maxproadmin More >>
Apollomics Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75% Posted on 2023-10-232024-03-13 by maxproadmin More >>
Apollomics Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023 Posted on 2023-10-162024-03-13 by maxproadmin More >>
Apollomics Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference Posted on 2023-09-062023-09-28 by maxproadmin More >>
